Published a list of foreign pharmaceutical companies financing the war of Russia against Ukraine

The CCD posted a list of these companies on its website, informs Espreso.TV.

Most of them are pharmaceutical companies from the United States - 15:

Johnson & Johnson, Pfizer, Merck Sharp & Dohme, Abbott, Bristol Myers Squibb, Eli Lilly, Viatris, Celgene, Organon, AbbVie Inc., Marathon Pharma, Amgen, Solgar, PTC Therapeutics, Unipharm, Inc.

The second place holds Germany, 9 companies:

Bayer HealthCare, STADA, Menarini, BOEHRINGER I, Merck & Co, Bionorica, WÖRWAG Pharma, MERZ & CO, FRESENIUS AG

The third - India, 6 companies:

Dr.  Reddy's, Sun Pharma, Glenmark, Innotech, Jodas Expoim Pvt Ltd, Sentiss Pharma Pvt Ltd

Next - France, Switzerland and the UK, 4 companies each:

French Sanofi-Aventis, Servier, BEAUFOUR IPSEN, Besins Healthcare

Swiss Roche, Novartis, Sandoz, Octapharma (together with Austria)

British GlaxoSmithKline, AstraZeneca, Reckitt Benckiser Group PLC, Eisai Europe Limited

Also, 3 Italian pharmaceutical companies remained on the Russian market: Recordati, Zambon, Alfasigma S.p.A.

2 companies each - from Japan (Takeda and Astellas Pharma Inc.), Czech Republic (PRO.MED.CS Praha as, Zentiva), Romania (Rompharm and Biotehnos), Ireland (Aspen Pharma Ireland Ltd and BioMarin), Latvia (Grindeks, Olainfarm  ) AS)

Israeli company Teva, Slovenian KRKA, Hungarian Gedeon Richter, Danish Novo Nordisk, Bulgarian Sopharm, Bosnian Bosnalijek, Canadian PharmaMed, Croatian Belupo and Belgian UCB.

Most pharmaceutical companies that remained to pay taxes on the territory of the aggressor country stopped any investments in the Russian economy and clinical trials in it.

As the representatives of the pharmaceutical business explain, they partially limited the supply of certain drugs to Russia, but according to international law, these restrictions do not apply to drugs needed by patients with cancer or diabetes and a number of other medicines.